TR201802334T4 - Th1 nitelikleri ve sitolitik özellikleri ifade eden hücreler. - Google Patents

Th1 nitelikleri ve sitolitik özellikleri ifade eden hücreler. Download PDF

Info

Publication number
TR201802334T4
TR201802334T4 TR2018/02334T TR201802334T TR201802334T4 TR 201802334 T4 TR201802334 T4 TR 201802334T4 TR 2018/02334 T TR2018/02334 T TR 2018/02334T TR 201802334 T TR201802334 T TR 201802334T TR 201802334 T4 TR201802334 T4 TR 201802334T4
Authority
TR
Turkey
Prior art keywords
cells
cell
tumor
patient
lethal
Prior art date
Application number
TR2018/02334T
Other languages
English (en)
Turkish (tr)
Inventor
Har-Noy Michael
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of TR201802334T4 publication Critical patent/TR201802334T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
TR2018/02334T 2010-08-20 2011-08-22 Th1 nitelikleri ve sitolitik özellikleri ifade eden hücreler. TR201802334T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US201161495055P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
TR201802334T4 true TR201802334T4 (tr) 2018-03-21

Family

ID=45594250

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/02334T TR201802334T4 (tr) 2010-08-20 2011-08-22 Th1 nitelikleri ve sitolitik özellikleri ifade eden hücreler.

Country Status (19)

Country Link
US (3) US20120045423A1 (cg-RX-API-DMAC7.html)
EP (1) EP2606125B1 (cg-RX-API-DMAC7.html)
JP (2) JP6408219B2 (cg-RX-API-DMAC7.html)
KR (1) KR101900807B1 (cg-RX-API-DMAC7.html)
CN (2) CN103068973A (cg-RX-API-DMAC7.html)
AU (1) AU2011291477B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013003989B1 (cg-RX-API-DMAC7.html)
CA (1) CA2808873C (cg-RX-API-DMAC7.html)
DK (1) DK2606125T3 (cg-RX-API-DMAC7.html)
ES (1) ES2660577T3 (cg-RX-API-DMAC7.html)
HU (1) HUE036094T2 (cg-RX-API-DMAC7.html)
IL (1) IL224813B (cg-RX-API-DMAC7.html)
NO (1) NO2606125T3 (cg-RX-API-DMAC7.html)
PH (1) PH12013500519B1 (cg-RX-API-DMAC7.html)
PL (1) PL2606125T3 (cg-RX-API-DMAC7.html)
PT (1) PT2606125T (cg-RX-API-DMAC7.html)
SG (2) SG10201510524TA (cg-RX-API-DMAC7.html)
TR (1) TR201802334T4 (cg-RX-API-DMAC7.html)
WO (1) WO2012024666A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024666A2 (en) * 2010-08-20 2012-02-23 Immunovative Therapies, Ltd. Cells expressing th1 characteristics and cytolytic properties
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
ATE457349T1 (de) 2002-08-23 2010-02-15 Multhoff Gabriele Prof Dr Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ, リミテッド 細胞治療のためのt細胞を調製するための方法
WO2012024666A2 (en) 2010-08-20 2012-02-23 Immunovative Therapies, Ltd. Cells expressing th1 characteristics and cytolytic properties

Also Published As

Publication number Publication date
US20120045423A1 (en) 2012-02-23
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
CA2808873A1 (en) 2012-02-23
US20130196428A1 (en) 2013-08-01
SG10201510524TA (en) 2016-01-28
KR20130103485A (ko) 2013-09-23
SG187846A1 (en) 2013-03-28
EP2606125B1 (en) 2017-11-22
PH12013500519B1 (en) 2020-06-26
HUE036094T2 (hu) 2018-06-28
PH12013500519A1 (en) 2013-05-06
IL224813B (en) 2020-06-30
WO2012024666A2 (en) 2012-02-23
ES2660577T3 (es) 2018-03-23
JP6408219B2 (ja) 2018-10-17
JP2013536232A (ja) 2013-09-19
JP2017061558A (ja) 2017-03-30
EP2606125A2 (en) 2013-06-26
CN103068973A (zh) 2013-04-24
AU2011291477B2 (en) 2016-07-28
DK2606125T3 (en) 2018-03-05
BR112013003989A2 (pt) 2017-11-14
JP6525946B2 (ja) 2019-06-05
CA2808873C (en) 2020-02-18
AU2011291477A1 (en) 2013-04-04
EP2606125A4 (en) 2014-03-19
KR101900807B1 (ko) 2018-11-08
NO2606125T3 (cg-RX-API-DMAC7.html) 2018-04-21
PT2606125T (pt) 2018-02-27
PL2606125T3 (pl) 2018-05-30
CN108245673A (zh) 2018-07-06
BR112013003989B1 (pt) 2020-11-24
US20130195825A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
Tonn et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92
Morris et al. NKT cell–dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs
Wolf et al. Novel treatment concepts for graft-versus-host disease
JP5792622B2 (ja) ナチュラルキラー細胞の製造方法
Li et al. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
Damodharan et al. Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation
AU2015354941B2 (en) Method for culturing natural killer cells using T cells
JP6525946B2 (ja) Th1特性と細胞溶解性を発現する細胞
WO2007056854A1 (en) Method of expanding double negative t cells
Romieu-Mourez et al. The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies
CN112779215A (zh) 用于体外扩增和活化自然杀伤细胞的细胞培养基
AU2017382271B2 (en) CCR2+Hematopoietic Stem Cells Mediate T Cell Activation In Adoptive Cell Therapy
EP4183871A1 (en) Process for preparing a composition comprising a combined cell population
Har-Noy et al. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity
Fozza et al. Regulatory T cells in stem cell transplantation: main characters or walk-on actors?
HK1257638A1 (en) Cells expressing th1 characteristics and cytolytic properties
HK1184498A (en) Cells expressing th1 characteristics and cytolytic properties
Li et al. Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance
Cullup et al. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL
EP4724570A1 (en) Small molecule based method of modifying t cells
Davison Dendritic cells, T-cells and their possible role in the treatment of leukaemia and lymphoma
CN112779216A (zh) 体外扩增和活化自然杀伤细胞的方法及其药物组合物